Inhibition of IkappaB kinase alpha (IKKα) or IKKbeta (IKKβ) plus forkhead box O (Foxo) abolishes skeletal muscle atrophy.
Two transcription factor families that are activated during multiple conditions of skeletal muscle wasting are nuclear factor κB (NF-κB) and forkhead box O (Foxo). There is clear evidence that both NF-κB and Foxo activation are sufficient to cause muscle fiber atrophy and they are individually required for at least half of the fiber atrophy during muscle disuse, but there is no work determining the combined effect of inhibiting these factors during a physiological condition of muscle atrophy. Here, we determined whether inhibition of Foxo activation plus inhibition of NF-κB activation, the latter by blocking the upstream inhibitor of kappaB kinases (IKKα and IKKβ), would prevent muscle atrophy induced by 7 days of cast immobilization. Results were based on measurements of mean fiber cross-sectional area (CSA) from 72 muscles transfected with 5 different mutant expression plasmids or plasmid combinations. Immobilization caused a 47% decrease in fiber CSA in muscles injected with control plasmids. Fibers from immobilized muscles transfected with dominant negative (d.n.) IKKα-EGFP, d.n. IKKβ-EGFP or d.n. Foxo-DsRed showed a 22%, 57%, and 76% inhibition of atrophy, respectively. Co-expression of d.n. IKKα-EGFP and d.n. Foxo-DsRed significantly inhibited 89% of the immobilization-induced fiber atrophy. Similarly, co-expression of d.n. IKKβ-EGFP and d.n. Foxo-DsRed inhibited the immobilization-induced fiber atrophy by 95%. These findings demonstrate that the combined effects of inhibiting immobilization-induced NF-κB and Foxo transcriptional activity has an additive effect on preventing immobilization-induced atrophy, indicating that NF-κB and Foxo have a cumulative effect on atrophy signaling and/or atrophy gene expression.
Department of Physical Therapy, University of Florida, 101 S. Newell Drive, Gainesville, FL 32610, USA.
S A
SA
Reed
S M
SM
Senf
E W
EW
Cornwell
S C
SC
Kandarian
A R
AR
Judge
D000818:Animals; D051858:Forkhead Transcription Factors / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D051550:I-kappa B Kinase / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D008297:Male; D018482:Muscle, Skeletal / Q000378:metabolism* / Q000473:pathology; D009133:Muscular Atrophy / Q000235:genetics* / Q000473:pathology; D009419:Nerve Tissue Proteins / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D010957:Plasmids / Q000235:genetics; D051381:Rats; D017207:Rats, Sprague-Dawley; D014158:Transcription, Genetic; D000071161:Forkhead Box Protein O1
D051858:Forkhead Transcription Factors; D051550:I-kappa B Kinase; D009419:Nerve Tissue Proteins; C074639:Foxo1 protein, rat; D000071161:Forkhead Box Protein O1
Acta Physiol Scand. 2004 Jun;181(2):233-8
15180796
Endocrinology. 2008 Mar;149(3):1407-14
18079193
FEBS Lett. 2003 Feb 11;536(1-3):232-6
12586369
FASEB J. 2004 Jan;18(1):39-51
14718385
Physiol Genomics. 2005 Apr 14;21(2):253-63
15687482
J Biol Chem. 2004 Sep 24;279(39):41114-23
15272020
J Clin Invest. 2006 Nov;116(11):2945-54
17080195
Int J Biochem Cell Biol. 2008;40(8):1425-30
17693123
Science. 2001 Nov 23;294(5547):1704-8
11679633
Cell. 1997 Oct 17;91(2):243-52
9346241
J Immunol. 2002 May 15;168(10):5024-31
11994454
J Appl Physiol (1985). 1986 Jun;60(6):1946-53
3722061
J Clin Invest. 2004 Nov;114(10):1504-11
15546001
Cell. 2004 Oct 15;119(2):285-98
15479644
Am J Physiol Cell Physiol. 2010 Jan;298(1):C38-45
19864323
FASEB J. 2009 Feb;23(2):362-70
18827022
FASEB J. 2008 Nov;22(11):3836-45
18644837
Am J Physiol Cell Physiol. 2007 Jan;292(1):C372-82
16928772
Mol Cell Biol. 2005 Oct;25(19):8520-30
16166634
FASEB J. 2002 Apr;16(6):529-38
11919155
Cell. 2004 Apr 30;117(3):399-412
15109499